HomeAIM • NYSEAMERICAN
AIM ImmunoTech Inc
$0.21
After Hours:
$0.21
(1.62%)+0.0034
Closed: Nov 22, 7:55:47 PM GMT-5 · USD · NYSEAMERICAN · Disclaimer
StockUS listed securityUS headquartered
Previous close
$0.21
Day range
$0.21 - $0.22
Year range
$0.16 - $0.62
Market cap
13.49M USD
Avg Volume
531.02K
P/E ratio
-
Dividend yield
-
In the news
Financials
Income Statement
Revenue
Net income
(USD)Sep 2024Y/Y change
Revenue
35.00K-23.91%
Operating expense
4.52M-44.74%
Net income
-3.70M52.66%
Net profit margin
-10.57K37.78%
Earnings per share
-0.0757.39%
EBITDA
-4.43M45.38%
Effective tax rate
Total assets
Total liabilities
(USD)Sep 2024Y/Y change
Cash and short-term investments
7.20M-67.89%
Total assets
13.59M-51.23%
Total liabilities
10.68M103.00%
Total equity
2.91M
Shares outstanding
63.71M
Price to book
4.23
Return on assets
-76.60%
Return on capital
-142.29%
Net change in cash
(USD)Sep 2024Y/Y change
Net income
-3.70M52.66%
Cash from operations
-3.11M45.16%
Cash from investing
334.00K199.40%
Cash from financing
137.00K-41.20%
Net change in cash
-2.64M54.30%
Free cash flow
-2.11M34.80%
About
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees. The company has created an immunomodulatory double stranded RNA drug called Ampligen. It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
Founded
1966
Employees
27
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu